News
ICVX
15.31
0.00%
0.00
Weekly Report: what happened at ICVX last week (0226-0301)?
Weekly Report · 03/04 09:10
Weekly Report: what happened at ICVX last week (0219-0223)?
Weekly Report · 02/26 09:11
M&A Funds And The Stocks Where There Is At Least A 3.5% Stake
Seeking Alpha · 02/20 22:40
Icosavax Acquisition by AstraZeneca Leads to Delisting and Corporate Changes
TipRanks · 02/20 13:52
Weekly Report: what happened at ICVX last week (0212-0216)?
Weekly Report · 02/19 09:11
Weekly Report: what happened at ICVX last week (0205-0209)?
Weekly Report · 02/12 09:11
Icosavax: Tender Offer With Contingent Value Right
Seeking Alpha · 02/11 11:01
Weekly Report: what happened at ICVX last week (0129-0202)?
Weekly Report · 02/05 09:11
Weekly Report: what happened at ICVX last week (0122-0126)?
Weekly Report · 01/29 09:11
Notable Wednesday Option Activity: MDB, BWA, ICVX
NASDAQ · 01/24 20:36
Eye Disruptive Medicine ETF FMED to Start 2024
NASDAQ · 01/24 19:45
Icosavax, Inc.: Statement of changes in beneficial ownership of securities
Press release · 01/24 00:06
Weekly Report: what happened at ICVX last week (0115-0119)?
Weekly Report · 01/22 09:11
Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled
Icosavax (ICVX) fell 1.7% as AstraZeneca withdrew its filing for HSR approval for the planned sale and refiled it. HSR filing for Astra Zeneca deal withdrawn, refiled to give FTC more time to review the deal.
Seeking Alpha · 01/19 15:13
Weekly Report: what happened at ICVX last week (0108-0112)?
Weekly Report · 01/15 09:11
Icosavax, Inc.: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/10 20:04
Weekly Report: what happened at ICVX last week (0101-0105)?
Weekly Report · 01/08 09:11
Icosavax, Inc.: Statement of changes in beneficial ownership of securities
Press release · 01/06 10:04
Icosavax CVR Seems Fairly Valued
AstraZeneca plans to acquire Icosavax for $15/share in cash and one non-tradable CVR per share. The CVR pays out $4/share upon FDA approval of the vaccine candidate and $1/ share upon achieving over $200M in sales. AstraZeneca is a pharmaceutical company developing vaccines for life-threatening diseases. The company's CVR is currently fairly valued.
Seeking Alpha · 01/05 20:45
Icosavax, Inc.: Report of proposed sale of securities
Press release · 01/04 22:59
More
Webull provides a variety of real-time ICVX stock news. You can receive the latest news about Icosavax, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ICVX
Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. It is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). It is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.